drugset / Trial / NCT04756427

Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition

NCT04756427

Phase 4 Terminated 1 enrolled Johns Hopkins University
NaSingle-groupOpen-labelPrevention

Summary

This study an open label prospective observational cohort study to evaluate the safety and efficacy of sodium citrate 4% locking solution in preventing central line associated blood stream infection in children requiring long term central venous catheters for home parenteral nutrition. Sodium citrate 4% is FDA-approved for dialysis catheters, but has not been formally evaluated for use in tunneled catheters for parenteral nutrition. The rate of central line-associated bloodstream infection (CLABSI) and other potential adverse events will be monitored for 12 months, with the option to remain in the study for a longer period of time.

Timeline

Start
2022-03-28
Primary completion
2023-11-28
Completion
2023-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium citrate Unknown 3 ml

Indications

No indication recorded.